Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for anxiety/depression in COPD
ChiCTR1800017338Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram in anxiety disorder, major depressive disorder (MDD) and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: Lung function, Clinical symptoms and 1 more. Started Sep 2016; status: recruiting.
02
Drugs
escitalopram
03
Conditions
anxiety disordermajor depressive disorder (MDD)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR1800017338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017338.